GSK Closes China Neuroscience Center In Latest R&D Reorganization
The axe comes sooner but was not unexpected, given past controversy and a fresh direction under the leadership of GSK's new CEO Emma Walmsley who once spent years in Shanghai, where the company’s China R&D center is located.
You may also be interested in...
Alector says upfront payment and earnouts will fully pay for development of AL101 and AL001 in frontotemporal dementia and indications including ALS, Alzheimer’s and Parkinson’s.
Early-stage venture capital funding in China continued to rise in Q3, while big Chinese companies are investing in foreign firms with an eye on access to new products and market expansion. Several healthcare funds were also set up to tap into emerging opportunities.
Top China executives from Pfizer, AstraZeneca, GSK share their views on growing in China amid lingering challenges despite regulatory progress.